Lecanemab-irmb

Brand names: Leqembi, Lecanemab Autoinjector · Active ingredient: Lecanemab, Lecanemab-Irmb

In short: LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Forms & strengthsLecanemab-irmb is a clear to very opalescent, colorless to pale yellow solution, available as: Intravenous Infusion Injection: 500 mg/5 mL (100 mg/mL) in a single-dose vial Injection: 200 mg/2 mL (100 mg/mL) in a single-dose vial Subcutaneous …
LabelEisai Inc.
Label updatedJul 27, 2026

What is Lecanemab-irmb used for?

LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

⚠ Boxed warning (FDA's strongest warning)

Monoclonal antibodies directed against aggregated forms of beta amyloid, including

LEQEMBI,

can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhage

s

> 1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI

.

ApoE ε4 Homozygotes

Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes

(approximately 15% of Alzheimer’s disease patients)

treated with

this class of medications, including LEQEMBI,

have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. …

Lecanemab-irmb dosage

Confirm the presence of amyloid beta pathology prior to initiating treatment .

Initiate LEQEMBI using a starting dosage regimen . After 18 months, the starting dosage regimen may be continued or a transition to a maintenance dosage regimen may be considered . Both the starting and maintenance dosage regimens can be administered by either intravenous infusion or subcutaneous injection. The route of administration can be switched. When switching the route of administration and simultaneously transitioning from the starting dosage regimen to the maintenance dosage regimen, see Table 2. When switching the route of administration during the starting dosage regimen or during the maintenance dosage regimen, see Dosage and Administration (

2.3

).

Table 1:

Starting Dosage Regimen

Route of Administration | Dose | Frequency | Infusion Rate

(if

i

ntravenous)

Intravenous (LEQEMBI) | 10 mg/kg | Once every 2 weeks | Over approximately one hour

Subcutaneous(LEQEMBI IQLIK) | 500 mg (two 250 mg injections) | Once every week | ------------------------

Table 2: Maintenance Dosage Regimen

Route of Administration | Dose | Frequency | Infusion Rate (if intravenous) | Time Interval Between Last Starting Dose and First Maintenance Dose

Intravenous (LEQEMBI) | 10 mg/kg | Once every 4 weeks | Over approximately one hour | If previously on intravenous starting dosage regimen: 2 weeksIf previously on subcutaneous starting dosage regimen: minimum of 2 weeks, but no more than 3 weeks

Subcutaneous (LEQEMBI IQLIK) | 360 mg | Once every week | — | 1 week(regardless of starting dosage regimen)

For intravenous infusion, use LEQEMBI vials. LEQEMBI vials must be diluted before administration .

For subcutaneous administration, use LEQEMBI IQLIK .

During the starting dosage regimen and maintenance dosage regimen, the route of administration (intravenous with LEQEMBI vials or subcutaneous with LEQEMBI IQLIK) may be switched as described below. Thereafter follow the dosing schedule for the new route of administration.

Switching Routes of Administration During the Starting Dosage Regimen

•

To switch from the intravenous to subcutaneous route of administration, administer the first subcutaneous dose 1 week after the last intravenous dose.

•

To switch from the subcutaneous to the intravenous route of administration, administer the first intravenous dose a minimum of 2 weeks, but no more than 3 weeks, after the last subcutaneous dose.

Switching Routes of Administration During the Maintenance Dosage Regimen

•

To switch from the intravenous to subcutaneous route of administration, administer the first subcutaneous dose 1 week after the last intravenous dose. …

How to take Lecanemab-irmb — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Amyloid Related Imaging Abnormalities

Inform patients that LEQEMBI may cause Amyloid Related Imaging Abnormalities or “ARIA”. ARIA most commonly presents as a temporary swelling in areas of the brain that usually resolves over time. Some people may also have small spots of bleeding in or on the surface of the brain. Inform patients that most people with swelling in areas of the brain do not experience symptoms; however, some people may experience symptoms such as headache, confusion, dizziness, vision changes, nausea, aphasia, weakness, or seizure. Instruct patients to notify their healthcare provider immediately if these symptoms occur. Clinical evaluation should be performed, and an MRI may be considered. Inform patients that serious symptoms of ARIA may occur and that ARIA can be fatal. …

Warnings & precautions

Do not take this medicine if: LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis .

Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E), which can be observed on MRI as brain edema or sulcal effusions, and ARIA with hemosiderin deposition (ARIA-H), which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with Alzheimer’s disease, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy, such as pretreatment microhemorrhage or superficial siderosis. ARIA-H associated with monoclonal antibodies directed against aggregated forms of beta amyloid generally occurs in association with an occurrence of ARIA-E. ARIA-H of any cause and ARIA-E can occur together.

ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. When present, reported symptoms associated with ARIA may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms associated with ARIA usually resolve over time. In addition to ARIA, intracerebral hemorrhages greater than 1 cm in diameter have occurred in patients treated with LEQEMBI.

Consider the benefit of LEQEMBI for the treatment of Alzheimer’s disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with LEQEMBI.

Incidence of ARIA

Symptomatic ARIA occurred in 3% (29/898) of patients treated with LEQEMBI in Study 2 . …

Lecanemab-irmb side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Amyloid Related Imaging Abnormalities

Hypersensitivity Reactions

Infusion-Related Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials with Intravenous Administration

The safety of LEQEMBI has been evaluated in 2090 patients who received at least one dose of LEQEMBI by intravenous infusion. In Studies 1 and 2 in patients with Alzheimer’s disease, 1059 patients received LEQEMBI 10 mg/kg every two weeks by intravenous infusion . Of these 1059 patients, 50% were female, 79% were White, 15% were Asian, 12% were of Hispanic or Latino ethnicity, and 2% were Black. The mean age at study entry was 72 years (range from 50 to 90 years).

In the combined double-blind, placebo-controlled period and long-term extension period of Studies 1 and 2, 1604 patients received LEQEMBI for at least 6 months, 1261 patients for at least 12 months, and 965 patients for 18 months. …

About this medicine

Lecanemab-irmb is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, and is expressed in a Chinese hamster ovary cell line. Lecanemab-irmb has an approximate molecular weight of 150 kDa.

LEQEMBI Injection for Intravenous Use

LEQEMBI (lecanemab-irmb) injection is a sterile, preservative-free, clear to very opalescent and colorless to pale yellow solution for intravenous infusion after dilution. LEQEMBI contains lecanemab-irmb at a concentration of 100 mg/mL in either a 500 mg/5 mL or 200 mg/2 mL single-dose vial.

Each mL of solution contains 100 mg of lecanemab-irmb and arginine hydrochloride (42.13 mg), histidine (0.18 mg), histidine hydrochloride monohydrate (4.99 mg), polysorbate 80 (0.50 mg), and Water for Injection at an approximate pH of 5.0.

LEQEMBI IQLIK Injection for Subcutaneous Use

LEQEMBI IQLIK (lecanemab-irmb) injection is a sterile, preservative-free, clear to very opalescent, colorless to pale yellow solution for subcutaneous use. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9d1ff786-e577-410a-a273-c4d7d0e4e975. Read the full official label on DailyMed.